17 completed, 7 active not recruiting, 5 recruiting, 3 unknown. 10 Phase 1, 9 Not applicable, 8 Phase 2, 4 Phase 3.
Follow Malignant Neoplasm of Breast: new trials by email Literature Review of Malignant Neoplasm of Breast trials Research Report on Malignant Neoplasm of Breast
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases Arm 1 - Breast Cancer, Breast Carcinoma | Recruiting | National Cancer Institute (NCI) | 139 | 2026-11-04 | 2026-10-30 | |
| TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer HTR2 T Cells - Breast Cancer, Tumor, Breast | Phase 1 | Recruiting | Baylor College of Medicine | 27 | 2026-08-03 | 2026-09-24 |
| A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast) Expression Networks for highLIGHting Tumor vulnerabilities (ENLIGHT), TruSight(R) Oncology 500, TruSeq Matched Tumor Normal Whole Exome Sequencing Assay - Breast Cancer, Breast Carcinoma | Not applicable | Recruiting | National Cancer Institute (NCI) | 175 | 2026-02-23 | 2026-08-21 |
| A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer Two Component Product CLBR001 + ABBV-461 - Breast Cancer Metastatic, Locally Advanced Breast Cancer (LABC) | Phase 1 | Terminated | Calibr, a division of Scripps Research | 10 | 2025-04-17 | 2026-05-28 |
| A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer Palbociclib, Aromatase inhibitor, Ribociclib - Breast Cancer, Malignant Neoplasm of Breast | Active not recruiting | Pfizer | 1 | 2024-06-24 | 2025-11-25 | |
| Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors Novilase Laser ablation - Malignant Neoplasm of Breast | Not applicable | Recruiting | Novian Health Inc. | 122 | 2023-08-09 | 2026-02-19 |
| Low-field MRI for Breast Cancer Screening Magnetic Resonance Imaging (MRI) - Breast Benign, Malignant Neoplasm of Breast | Not applicable | Enrolling by invitation | Massachusetts General Hospital | 40 | 2022-09-01 | 2026-10-07 |
| Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO Pembrolizumab Injection [Keytruda], Olaparib Oral Tablet [Lynparza] - Malignant Neoplasm of Breast, Breast Cancer | Phase 2 | Active not recruiting | Institut fuer Frauengesundheit | 11 | 2022-07-30 | 2024-05-07 |
| Therapeutic Dose Monitoring (TDM) of Tamoxifen Tamoxifen 20 mg - Breast Cancer, Breast Carcinoma | Phase 2 | Unknown | Karolinska University Hospital | 40 | 2022-04-04 | 2022-05-25 |
| Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA) Imprime PGG, Pembrolizumab - Malignant Neoplasm of Breast | Phase 2 | Completed | HiberCell, Inc. | 26 | 2021-11-09 | 2023-06-22 |
| Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors Enhanced Usual Care, Acceptance Commitment Therapy, Cognitive Behavioral Therapy - Breast Neoplasm, Breast Cancer | Not applicable | Completed | Indiana University | 390 | 2021-08-17 | 2024-12-04 |
| Accelerated Partial Breast Irradiation Versus Standard or Hypofractionated Whole-Breast Irradiation, in Early Breast Cancer, After Breast-conserving Surgery Active Comparator: Standard, Experimental 1: Hypofractionated radiotherapy, Experimental 2: Accelerated Partial Breast Irradiation - Malignant Neoplasm of Breast | Not applicable | Recruiting | Instituto Brasileiro de Controle do Cancer | 36 | 2021-03-04 | 2021-03-08 |
| Swedish Ibrance Registries Insights (SIRI) palbociclib - Malignant Neoplasm of Breast | Completed | Pfizer | 1500 | 2020-12-15 | 2026-10-22 | |
| MIRs 04 : Interpectoral Nerve Block With Ropivacaine Versus Placebo Before Breast Cancer Surgery Saline, Ropivacaine - Malignant Neoplasm of Breast | Phase 3 | Completed | Institut Curie | 182 | 2020-08-04 | 2025-09-19 |
| Breast Reconstruction Following Breast Cancer in Very High Risk Patients Immediate Breast Reconstruction, Delayed Breast Reconstruction, Breast-Q questionnaire - Breast Cancer, Malignant Neoplasm of Breast | Not applicable | Withdrawn | Case Comprehensive Cancer Center | 2019-05-31 | 2022-05-20 | |
| Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT Pembrolizumab, Clostridium Novyi-NT, Doxycycline - Malignant Neoplasm of Breast, Malignant Neoplasms of Digestive Organs | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 18 | 2018-07-10 | 2026-04-16 |
| Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC Pembrolizumab, nab-paclitaxel, Epirubicin - Malignant Neoplasm of Breast | Phase 2 | Completed | Institut fuer Frauengesundheit | 53 | 2018-03-23 | 2021-04-08 |
| Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer DS-8201a - Malignant Neoplasm of Breast | Phase 1 | Completed | Daiichi Sankyo Co., Ltd. | 51 | 2017-12-26 | 2022-04-12 |
| An Early Stress-Reduction Intervention in Patients With Newly Diagnosed Breast Cancer Mind-Body Exercises, Questionnaires - Malignant Neoplasm of Breast | Not applicable | Active not recruiting | M.D. Anderson Cancer Center | 62 | 2017-12-05 | 2026-06-02 |
| Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer Trastuzumab, Ibrutinib 560 mg, Ibrutinib 840 mg - Breast Neoplasms, Malignant Neoplasm of Breast | Phase 1 / Phase 2 | Active not recruiting | US Oncology Research | 34 | 2017-11-29 | 2024-12-06 |
Showing 20 of 37. Sign in to see all of them.
Breast Neoplasms (37) · Triple Negative Breast Neoplasms (5) · Anxiety Disorders (2) · Urologic Neoplasms (2) · Central Nervous System Neoplasms (1) · Chronic Pain (1) · Colonic Neoplasms (1) · Gastrointestinal Neoplasms (1) · Glioma (1) · Head and Neck Neoplasms (1) · Hodgkin Disease (1) · Lymphoma, Non-Hodgkin (1) · Mammary Neoplasms, Animal (1) · Melanoma (1) · Neoplasm Regression, Spontaneous (1)
Breast Diseases (37) · Neoplasms by Site (37) · Skin Diseases (37) · Skin and Connective Tissue Diseases (37) · Neoplasms (36) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Neoplasms by Histologic Type (3) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Gastrointestinal Diseases (2) · Male Urogenital Diseases (2) · Mental Disorders (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Nerve Tissue (2)
pembrolizumab (4) · Acceptance and Commitment Therapy (2) · Albumin-Bound Paclitaxel (2) · Capecitabine (2) · Cyclophosphamide (2) · MLN 8237 (2) · Paclitaxel (2) · Ropivacaine (2) · Sodium Chloride (2) · Trastuzumab (2) · olaparib (2) · palbociclib (2) · 130-nm albumin-bound paclitaxel (1) · AZD 6244 (1) · Anastrozole (1)
M.D. Anderson Cancer Center (4) · Pfizer (3) · Indiana University (2) · Institut Curie (2) · Institut fuer Frauengesundheit (2) · National Cancer Institute (NCI) (2) · US Oncology Research (2) · Washington University School of Medicine (2) · AryoGen Pharmed Co. (1) · Baylor College of Medicine (1) · Bryan Schneider, MD (1) · Calibr, a division of Scripps Research (1) · Case Comprehensive Cancer Center (1) · Daiichi Sankyo Co., Ltd. (1) · HiberCell, Inc. (1)
United States (21) · Germany (4) · Israel (3) · Brazil (2) · France (2) · Sweden (2) · China (1) · Iran (1) · Italy (1) · Japan (1) · Singapore (1) · Switzerland (1) · Taiwan (1) · United Kingdom (1)
Shelley A Johns, PsyD (2) · Alison Stopeck, MD (1) · Arkadiusz Z. Dudek, M.D. (1) · Binghe XU, MD (1) · Bryan Schneider, M.D. (1) · Cleiton C Queiroz, BSc (1) · David S. Hong, MD (1) · Diethelm Wallwiener, Prof. Dr. (1) · Dino Amadori, MD (1) · Elham Hedayati, MD PhD (1) · John Lewin, MD (1)
PMID 11020770, PMID 16698416, PMID 19903919, PMID 23340346, PMID 23340351, PMID 28341957, PMID 30973373, PMID 31050919, PMID 32379297, PMID 32644110, PMID 33498797, PMID 33877311, PMID 33970392, PMID 34910554, PMID 35567914, PMID 36164935, PMID 38745646, PMID 40068583, PMID 40691446, PMID 41830752, PMID 41950642, PMID 42095602, PMID 42324670, PMID 42400053, PMID 42504645
2009 (1), 2016 (1), R01CA255480 (1), R01EB002136 (1)